ArticleMolecular cancer therapeutics2019
KDM5B Promotes Drug Resistance by Regulating Melanoma-Propagating Cell Subpopulations.
Abstract read
In one paragraph
Article in Molecular cancer therapeutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 53 citations in OpenAlex.
- JARID1B-Mediated H3K4me3 Demethylation Promotes Cisplatin Resistance in Oral Squamous Cell Carcinoma Cells via the miR-495-3p/FUBP1 Axis.Applied biochemistry and biotechnology · 2026Article
- Catestatin peptide impedes melanoma progression and drug resistance by reprogramming oncogenic signaling pathways.Oncogenesis · 2026Article
- Catestatin peptide impedes melanoma progression and drug resistance by reprogramming oncogenic signaling pathways.Research square · 2026Article
- Catestatin suppresses melanoma progression and drug resistance through multitargeted modulation of signaling pathways.bioRxiv : the preprint server for biology · 2025Article
- Roles of KDM5 demethylases in therapeutic resistance of cancers.Epigenetics & chromatin · 2025Review
- DNA Methyltransferase Inhibition Upregulates the Costimulatory Molecule ICAM-1 and the Immunogenic Phenotype of Melanoma Cells.JID innovations : skin science from molecules to population health · 2025Article
- Epigenetic Modifiers in Cancer Metastasis.Biomolecules · 2024Review
- The emerging roles of histone demethylases in cancers.Cancer metastasis reviews · 2024Review
- KDM5B promotes SMAD4 loss-driven drug resistance through activating DLG1/YAP to induce lipid accumulation in pancreatic ductal adenocarcinoma.Cell death discovery · 2024Article
- Diapause-like Drug-Tolerant Persister State: The Key to Nirvana Rebirth.Medicina (Kaunas, Lithuania) · 2024Review
- Targeting drug-tolerant cells: A promising strategy for overcoming acquired drug resistance in cancer cells.MedComm · 2023Review
- BRWD3 promotes KDM5 degradation to maintain H3K4 methylation levels.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Epigenetic markers and therapeutic targets for metastasis.Cancer metastasis reviews · 2023Review
- BRWD3 promotes KDM5 degradation to maintain H3K4 methylation levels.bioRxiv : the preprint server for biology · 2023Article
- Targeting epigenetic regulators to overcome drug resistance in cancers.Signal transduction and targeted therapy · 2023Review
- Characteristics and molecular mechanism of drug-tolerant cells in cancer: a review.Frontiers in oncology · 2023Review
- KDM5 Lysine Demethylases in Pathogenesis, from Basic Science Discovery to the Clinic.Advances in experimental medicine and biology · 2023Article
- Biophysical informatics reveals distinctive phenotypic signatures and functional diversity of single-cell lineages.Bioinformatics (Oxford, England) · 2023Article
- Epigenetic Mechanisms Underlying Melanoma Resistance to Immune and Targeted Therapies.Cancers · 2022Review
- Overcoming radio-resistance in esophageal squamous cell carcinoma via hypermethylation of PIK3C3 promoter region mediated by KDM5B loss.Journal of radiation research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Xiaoni Liu *Department of Pathology, Yale School of Medicine, New Haven, Connecticut.
Shang-Min Zhang *Department of Pathology, Yale School of Medicine, New Haven, Connecticut.
Meaghan K McGearyDepartment of Pathology, Yale School of Medicine, New Haven, Connecticut.ORCID 0000-0002-8505-7158
Irina KrykbaevaDepartment of Pathology, Yale School of Medicine, New Haven, Connecticut.
Ling LaiPenn Cardiovascular Institute, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Daniel J JansenNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland.
Stephen C KalesNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland.
Anton SimeonovNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland.
Matthew D HallNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland.
Daniel P KellyPenn Cardiovascular Institute, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.ORCID 0000-0002-3811-9491
Marcus W Bosenberg *Department of Pathology, Yale School of Medicine, New Haven, Connecticut. qin.yan@yale.edu marcus.bosenberg@yale.edu.
Qin Yan *Department of Pathology, Yale School of Medicine, New Haven, Connecticut. qin.yan@yale.edu marcus.bosenberg@yale.edu.
Yale University · USNational Center for Advancing Translational Sciences · USUniversity of Pennsylvania · US
Funding
Yale Pathology Tissue Services Shared ResourceP30CA016359 · NCI · YALE UNIVERSITY · PI DAVID L RIMM · 1985 to 2026
$85.0MYale SPORE in Skin CancerP50CA121974 · NCI · YALE UNIVERSITY · PI DAVID F STERN · 2006 to 2026
$43.9MMEDICAL SCIENTIST TRAINING PROGRAMT32GM007205 · NIGMS · YALE UNIVERSITY · PI KAZMIERCZAK, BARBARA I · 1985 to 2019
$42.9MTumor Assessment CoreP01CA128814 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI SMITH, JEFFREY W · 2009 to 2020
$19.1MYale Cancer Biology Training GrantT32CA193200 · NCI · YALE UNIVERSITY · PI PETER M GLAZER, Qin Yan · 2016 to 2026
$3.6MCongenic Mouse Medels of Melanoma for the Characterization of Tumor Immune ResponsesR01CA196660 · NCI · YALE UNIVERSITY · PI BOSENBERG, MARCUS W · 2016 to 2018
$1.7MAdvanced development of human KDM5 inhibitors (Chemical Biology Consortium/NCI Experimental Therapeutics Collaboration)ZIATR000273 · NCATS · NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES · PI HALL, MATTHEW · 2016 to 2018
$123kModeling the Immune Response to Melanoma Brain Metastases in MiceF30CA228444 · NCI · YALE UNIVERSITY · PI KRYKBAEVA, IRINA · 2018 to 2020
$110kIntramural NIH HHS ZIA TR000273NCI NIH HHS F30 CA228444NCI NIH HHS P01 CA128814NCI NIH HHS P30 CA016359NCI NIH HHS P50 CA121974NCI NIH HHS R01 CA196660NCI NIH HHS T32 CA193200NIGMS NIH HHS T32 GM007205
Abstract
Tumor heterogeneity is a major challenge for cancer treatment, especially due to the presence of various subpopulations with stem cell or progenitor cell properties. In mouse melanomas, both CD34
Indexed as
AnimalsAntigens, CD34Cell LineageCell Line, TumorCell ProliferationDNA-Binding ProteinsDrug Resistance, NeoplasmHumansJumonji Domain-Containing Histone DemethylasesMAP Kinase Kinase Kinase 1MelanomaMiceMutationProtein Kinase InhibitorsProto-Oncogene Proteins B-rafSulfonamidesAntigens, CD34Braf protein, mouseDNA-Binding ProteinsJumonji Domain-Containing Histone DemethylasesKdm5b protein, mouseMAP Kinase Kinase Kinase 1Protein Kinase InhibitorsProto-Oncogene Proteins B-rafSulfonamidesVemurafenib
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.